Avadel Pharmaceuticals to Present at BIO Digital
DUBLIN, Ireland, June 08, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals (Nasdaq: AVDL) announced that CEO Greg Divis and CMO Jordan Dubow will present at BIO Digital from June 8-12, 2020. The focus will be on FT218, a once-nightly sodium oxybate formulation targeting excessive daytime sleepiness and cataplexy in narcolepsy patients. The Phase 3 Rest-On clinical trial reported positive results. The presentation will be available on-demand during the conference at this link.
- None.
- None.
DUBLIN, Ireland, June 08, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced that Greg Divis, Chief Executive Officer of Avadel, and Jordan Dubow, M.D., Chief Medical Officer of Avadel, will present a corporate overview at BIO Digital from June 8-12, 2020.
The presentation will focus on the development of once-nightly FT218 and positive results from the Phase 3 Rest-On clinical trial. The presentation will be available on-demand during the conference via https://www.bio.org/events/bio-digital/sessions/693802.
About Avadel Pharmaceuticals plc:
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is an emerging biopharmaceutical company. The Company’s primary focus is the development and potential FDA approval of FT218, which has completed a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. In addition, Avadel markets a portfolio of sterile injectable drugs used in the hospital setting. For more information, please visit www.avadel.com.
| Contacts: | |
| 2%; width: | 98%; width: Tom McHugh Chief Financial Officer Phone: (636) 449-1843 Email: tmchugh@avadel.com |
| Tim McCarthy LifeSci Advisors, LLC Phone: (212) 915.2564 Email: tim@lifesciadvisors.com | |
| Media Contact Patrick Bursey LifeSci Communications, LLC Phone: (646) 970-4688 Email: pbursey@lifescicomms.com |
FAQ
What is the focus of Avadel Pharmaceuticals' presentation at BIO Digital?
When will Avadel Pharmaceuticals' presentation at BIO Digital take place?
What are the key results shared in the presentation by Avadel Pharmaceuticals?
Where can I watch the Avadel Pharmaceuticals presentation from BIO Digital?
What is the significance of FT218 for patients with narcolepsy?
